BRAF and metastatic melanoma: The treatment of metastatic melanoma is currently based on two main pillars: targeted therapy addressing BRAF (v-Raf murine sarcoma viral oncogene homolog B)/MEK (Mitogen-activated protein kinase kinase) in BRAF-mutant melanoma patients, and immune therapy, applied irrespective of the driver mutation.